These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 11060766)

  • 21. K+ channel blockade in the prevention of ventricular fibrillation in dogs with acute ischemia and enhanced sympathetic activity.
    Vanoli E; Hull SS; Adamson PB; Foreman RD; Schwartz PJ
    J Cardiovasc Pharmacol; 1995 Dec; 26(6):847-54. PubMed ID: 8606519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications.
    Chung MK; Schweikert RA; Wilkoff BL; Niebauer MJ; Pinski SL; Trohman RG; Kidwell GA; Jaeger FJ; Morant VA; Miller DP; Tchou PJ
    J Am Coll Cardiol; 1998 Jul; 32(1):169-76. PubMed ID: 9669266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sympathetic activation, ventricular repolarization and Ikr blockade: implications for the antifibrillatory efficacy of potassium channel blocking agents.
    Vanoli E; Priori SG; Nakagawa H; Hirao K; Napolitano C; Diehl L; Lazzara R; Schwartz PJ
    J Am Coll Cardiol; 1995 Jun; 25(7):1609-14. PubMed ID: 7759713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of ibutilide on spontaneous and induced ventricular arrhythmias in 24-hour canine myocardial infarction: a comparative study with sotalol and encainide.
    Buchanan LV; Kabell G; Turcotte UM; Brunden MN; Gibson JK
    J Cardiovasc Pharmacol; 1992 Feb; 19(2):256-63. PubMed ID: 1376795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction.
    Drexler AP; Micklas JM; Brooks RR
    J Cardiovasc Pharmacol; 1996 Dec; 28(6):848-55. PubMed ID: 8961084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical safety profile of sotalol in the treatment of arrhythmias.
    MacNeil DJ; Davies RO; Deitchman D
    Am J Cardiol; 1993 Aug; 72(4):44A-50A. PubMed ID: 8346726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest.
    Haverkamp W; Martinez-Rubio A; Hief C; Lammers A; Mühlenkamp S; Wichter T; Breithardt G; Borggrefe M
    J Am Coll Cardiol; 1997 Aug; 30(2):487-95. PubMed ID: 9247523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sotalol.
    Hohnloser SH; Woosley RL
    N Engl J Med; 1994 Jul; 331(1):31-8. PubMed ID: 8202100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolving role of sotalol in the management of ventricular tachyarrhythmias.
    O'Callaghan PA; McGovern BA
    Am J Cardiol; 1996 Aug; 78(4A):54-60. PubMed ID: 8780329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sotalol: a novel beta-blocker with class III anti-arrhythmic activity.
    Leibowitz D
    J Clin Pharmacol; 1993 Jun; 33(6):508-12. PubMed ID: 8366175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sotalol.
    Kpaeyeh JA; Wharton JM
    Card Electrophysiol Clin; 2016 Jun; 8(2):437-52. PubMed ID: 27261833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiarrhythmic actions of DL-sotalol in ventricular and supraventricular arrhythmias.
    Singh BN
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S75-90. PubMed ID: 1279313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New antiarrhythmic drug in pediatric use: sotalol.
    Pfammatter JP; Paul T
    Pediatr Cardiol; 1997; 18(1):28-34. PubMed ID: 8960489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Azimilide dihydrochloride, a novel antiarrhythmic agent.
    Karam R; Marcello S; Brooks RR; Corey AE; Moore A
    Am J Cardiol; 1998 Mar; 81(6A):40D-46D. PubMed ID: 9537222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term antiarrhythmic efficacy and safety of d-sotalol in patients with ventricular tachycardia and a low ejection fraction.
    Koch KT; Düren DR; van Zwieten PA
    Cardiovasc Drugs Ther; 1995 Jun; 9(3):437-43. PubMed ID: 8527354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiarrhythmic and electrophysiological effects of GYKI-16638, a novel N-(phenoxyalkyl)-N-phenylalkylamine, in rabbits.
    Baczkó I; El-Reyani NE; Farkas A; Virág L; Iost N; Leprán I; Mátyus P; Varró A; Papp JG
    Eur J Pharmacol; 2000 Sep; 404(1-2):181-90. PubMed ID: 10980278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of ventricular fibrillation by dextrorotatory sotalol in a conscious canine model of sudden coronary death.
    Lynch JJ; Coskey LA; Montgomery DG; Lucchesi BR
    Am Heart J; 1985 May; 109(5 Pt 1):949-58. PubMed ID: 3993529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.